Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 681
Filtrar
4.
Science ; 377(6603): 259-260, 2022 07 15.
Artículo en Inglés | MEDLINE | ID: mdl-35857602
5.
Am J Health Syst Pharm ; 78(14): 1294-1308, 2021 07 09.
Artículo en Inglés | MEDLINE | ID: mdl-33880494

RESUMEN

PURPOSE: To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2021 in the United States, with a focus on the nonfederal hospital and clinic sectors. METHODS: Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2021 were reviewed-including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, generics, coronavirus disease 2019 (COVID-19) pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2021 were based on a combination of quantitative analyses and expert opinion. RESULTS: In 2020, overall pharmaceutical expenditures in the United States grew 4.9% compared to 2019, for a total of $535.3 billion. Utilization (a 2.9% increase) and new drugs (a 1.8% increase) drove this increase, with price changes having minimal influence (a 0.3% increase). Adalimumab was the top drug in 2020, followed by apixaban and insulin glargine. Drug expenditures were $35.3 billion (a 4.6% decrease) and $98.4 billion (an 8.1% increase) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals the decrease in expenditures was driven by reduced utilization. Several new drugs that will influence spending are expected to be approved in 2021. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. CONCLUSION: For 2021, we expect overall prescription drug spending to rise by 4% to 6%, whereas in clinics and hospitals we anticipate increases of 7% to 9% and 3% to 5%, respectively, compared to 2020. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.


Asunto(s)
COVID-19/economía , Costos de los Medicamentos/tendencias , Economía Farmacéutica/tendencias , Gastos en Salud/tendencias , Medicamentos bajo Prescripción/economía , Biosimilares Farmacéuticos/economía , Biosimilares Farmacéuticos/uso terapéutico , COVID-19/epidemiología , Bases de Datos Factuales/tendencias , Medicamentos Genéricos/economía , Medicamentos Genéricos/uso terapéutico , Política de Salud/economía , Política de Salud/tendencias , Humanos , Farmacia/tendencias , Medicamentos bajo Prescripción/uso terapéutico , Estados Unidos/epidemiología , Tratamiento Farmacológico de COVID-19
6.
Am J Health Syst Pharm ; 77(24): 2140, 2020 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-33031507
7.
Ceska Slov Farm ; 69(3): 121-129, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32972155

RESUMEN

Bioactive metal complexes represent a promising and rapidly evolving area of pharmacotherapy. After the first part of our survey on metallopharmaceuticals dealing with antimicrobial activity of metal complexes and their application in diagnostics and the second part dedicated to anticancer properties of these compounds, this third and last part of the review focuses on several other applications of metals in therapy (mainly on the therapy of rheumatoid arthritis, some mental diseases, diabetes, as well as on chelation therapy). Following a brief account of the historical development of clinical use of the respective category of drugs, their chemical properties, toxicity, clinical applications and mechanism of action are discussed. The aim of this brief survey is to provide basic outline of the area of metallopharmacy, aimed at specialists in pharmacy and chemistry as well as at the general educated public.


Asunto(s)
Complejos de Coordinación/farmacología , Medicina/tendencias , Farmacia/tendencias , Metales/farmacología
8.
Am J Health Syst Pharm ; 77(22): 1874-1884, 2020 10 30.
Artículo en Inglés | MEDLINE | ID: mdl-32710774

RESUMEN

PURPOSE: The coronavirus disease 2019 (COVID-19) pandemic has created unprecedented challenges for health systems around the world. We describe our approach to adapting the pharmacy leadership structure to address critical medication shortages through innovative data analysis, procurement strategies, and rapid implementation of medication policy. SUMMARY: Yale New Haven Health deployed a system incident management command structure to effectively respond to the COVID-19 crisis. System pharmacy services adopted a similar framework to enable efficient communication and quick decision-making in key domains, including drug procurement and policy. By refining a model to project health-system medication needs, we were able to anticipate challenges and devise alternative treatment algorithms. By leveraging big data and creating a system knowledge base, we were able to consolidate reporting and coordinate efforts to ensure system success. Various procurement strategies were employed to ensure adequate supply, including frequent communication with our wholesaler, sourcing direct from suppliers, outsourcing of sterile products compounding to registered 503B outsourcing facilities, and acquisition of active pharmaceutical ingredients for compounding of essential medications. Strategic positioning of pharmacists within the health system's incident command response teams and rapid adaption of drug use policy governance fueled accelerated response and nimble implementation. Communication was streamlined and executed via multiple outlets to reach a broad audience across the health system. CONCLUSION: With medication shortages posing a threat to patient care, dynamic pharmacy leadership proved essential to providing patient care at the height of the COVID-19 pandemic. System alignment and the rapid adaption of the existing framework for drug shortage management and medication use policy were crucial to success in crisis response.


Asunto(s)
Infecciones por Coronavirus , Formularios de Hospitales como Asunto/normas , Liderazgo , Pandemias , Atención al Paciente/tendencias , Preparaciones Farmacéuticas/provisión & distribución , Servicio de Farmacia en Hospital/organización & administración , Farmacia/tendencias , Neumonía Viral , Centros Médicos Académicos , COVID-19 , Connecticut , Formularios Farmacéuticos como Asunto , Humanos , Comunicación Interdisciplinaria , Sistemas de Medicación en Hospital , Farmacéuticos
11.
Am J Health Syst Pharm ; 77(10): 759-770, 2020 05 07.
Artículo en Inglés | MEDLINE | ID: mdl-32378716

RESUMEN

PURPOSE: This article identifies, prioritizes, and summarizes published literature on the medication-use process (MUP) from calendar year 2018 that can impact health-system pharmacy daily practice. The MUP is the foundational system that provides the framework for safe medication utilization within the healthcare environment. The MUP is defined in this article as having the following steps: prescribing/transcribing, dispensing, administration, and monitoring. Articles that evaluated one of the steps were gauged for their usefulness toward daily practice change. SUMMARY: A PubMed search was conducted in February 2019 for articles published in calendar year 2018 using targeted Medical Subject Headings (MeSH) keywords, targeted non-MeSH keywords, and the table of contents of selected pharmacy journals, providing a total of 43,977 articles. A thorough review identified 62 potentially significant articles: 9 for prescribing/transcribing, 12 for dispensing, 13 for administration, and 28 for monitoring. Ranking of the articles for importance by peers led to the selection of key articles from each category. The highest-ranked articles are briefly summarized, with a mention of why they are important within health-system pharmacy. The other articles are listed for further review and evaluation. CONCLUSION: It is important to routinely review the published literature and to incorporate significant findings into daily practice. This article assists in identifying and summarizing recent impactful contributions to the MUP literature. Health-system pharmacists have an active role in improving the MUP in their institution, and awareness of significant published studies can assist in changing practice at the institutional level.


Asunto(s)
Utilización de Medicamentos/normas , Publicaciones Periódicas como Asunto/normas , Farmacéuticos/normas , Servicio de Farmacia en Hospital/normas , Farmacia/normas , Utilización de Medicamentos/tendencias , Humanos , Publicaciones Periódicas como Asunto/tendencias , Farmacéuticos/tendencias , Farmacia/tendencias , Servicio de Farmacia en Hospital/tendencias
13.
J Manag Care Spec Pharm ; 26(8): 952-955, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32329404

RESUMEN

Early reports of potential treatment for coronavirus disease (COVID-19) have raised concerns related to pharmaceutical distribution. Despite the lack of high-quality evidence, the mere hope of effectiveness of potential treatments, such as hydroxychloroquine, has led to surges in demand for these products, and many pharmacists are already informally reporting shortages through social channels. As manufacturers and wholesale distributors struggle to fulfill orders for drugs such as hydroxychloroquine, short-term price increases may seem reasonable in a free market when demand increases. However, any price increases by manufacturers, wholesale distributors, and pharmacies might be seen as exploitive gouging of consumers during a declared emergency. In addition to concerns of price gouging, increases in prescription drug utilization during the pandemic may lead to increases in spending for all payers as members may be treated for COVID-19. This article explores pharmaceutical supply chain and drug pricing nuances that may cause problems for payers and pharmacies as the country battles this global pandemic. DISCLOSURES: No funding supported the writing of this article. Mattingly reports unrelated consulting fees from the National Health Council, Bristol Myers Squibb, G&W Laboratories, Allergy and Asthma Foundation of American, and the Massachusetts Health Policy Commission. Hogue has nothing to disclose.


Asunto(s)
Infecciones por Coronavirus , Costos de los Medicamentos/ética , Pandemias , Preparaciones Farmacéuticas/provisión & distribución , Farmacia/tendencias , Neumonía Viral , COVID-19 , Ética Farmacéutica , Política de Salud , Humanos , Servicios Farmacéuticos , Estados Unidos
14.
Ann Pharmacother ; 54(9): 907-920, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32115996

RESUMEN

Objective: To review specific literature that aimed to predict the future of US pharmacy, beginning in the late 1980s. Data Sources: Articles were identified from searching MEDLINE, CINAHL, Google Scholar, and references of relevant articles. The following combinations of search terms were used: future, pharmacy, prediction, and forecast. Study Selection and Data Extraction: The following inclusion criteria were applied: (1) full-text commentary, review, or original research and (2) focused predominantly on the pharmacy in the United States. Data on predictions for the future of pharmacy were extracted. Data Synthesis: We selected 3 articles published between 1988 and 2006, with each aiming to project the future for the following decade. We examined each prediction in light of the current knowledge. Relevance to Patient Care and Clinical Practice: Educators, practitioners, and other stakeholders should consider reflecting on the changes in pharmacy for the past 3 decades and applying both historical and emerging trends to improve patient care and sustain practice in the third decade of the 21st century and beyond. Conclusion: Most of the predictions for the future of pharmacy from the past 3 decades materialized, with some still in progress (reimbursement for pharmacy services), whereas others manifested in unexpected ways (transition from shortage to excess of pharmacists). Current forces shaping pharmacy include, but are not limited to, growing spending and use of specialty drugs, automation of pharmacy operations, growth of pharmacy in the digital health enterprise, and growing consumer interest in the use of analytical pharmacy that tests drugs before dispensing.


Asunto(s)
Servicios Farmacéuticos , Farmacia/tendencias , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Atención al Paciente/normas , Atención al Paciente/tendencias , Servicios Farmacéuticos/historia , Servicios Farmacéuticos/tendencias , Farmacias/historia , Farmacias/tendencias , Farmacéuticos/normas , Farmacéuticos/tendencias , Estados Unidos
18.
19.
J Oncol Pharm Pract ; 26(1): 175-186, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31554471

RESUMEN

Gender disparity exists in leadership roles within healthcare. While the majority of the healthcare workforce is comprised of women, significantly fewer women occupy leadership positions, particularly at executive and board levels. As the field of oncology pharmacy continues to rapidly expand and evolve, an assessment of the current state of women in oncology pharmacy leadership roles is vital to the growth and development of the profession. In the fall of 2017, the Hematology/Oncology Pharmacy Association (HOPA) hosted a summit to explore leadership issues facing women in oncology pharmacy which have the potential to affect our membership and our profession. This meeting included invited participants from across the fields of oncology and pharmacy and was part of HOPA's strategic leadership initiative developed through the work of the HOPA Leadership Development Committee in 2016. This promotes a primary goal of HOPA, which is to support oncology pharmacists as they assume leadership roles within their practices and within healthcare to assure oncology pharmacy is integrated into cancer care. The purpose of this white paper is to (1) summarize key issues that were identified through a membership survey; (2) review ongoing efforts to address the needs of female oncology pharmacists in leadership development; (3) serve as a call to action for individuals and professional organizations to assist with and disseminate these efforts and highlight available resources, and (4) to provide practical steps to meet the needs of individuals, training programs, and institutions/employers.


Asunto(s)
Liderazgo , Neoplasias/tratamiento farmacológico , Farmacéuticos/tendencias , Farmacia/tendencias , Sexismo/tendencias , Femenino , Humanos , Servicios Farmacéuticos/tendencias , Farmacia/métodos , Sexismo/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...